Education
About Us
Working with TipRanks
Follow Us
Alkermes (ALKS)
NASDAQ:ALKS
ALKS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$22.90 - $36.45
Previous CloseN/A
Volume176.14K
Average Volume (3M)1.78M
Market Cap
$5.40B
Enterprise Value$4.11B
Total Cash (Recent Filing)$291.15M
Total Debt (Recent Filing)$75.54M
Price to Earnings (P/E)15.2
Beta0.87
Next Earnings
Apr 23, 2025EPS Estimate
0.31Last Dividend Ex-Date
Nov 16, 2023Dividend YieldN/A
Share Statistics
EPS (TTM)2.18
Shares Outstanding162,614,060
10 Day Avg. Volume1,675,507
30 Day Avg. Volume1,781,404
Financial Highlights & Ratios
PEG Ratio3.34
Price to Book (P/B)N/A
Price to Sales (P/S)3.61
Price to Cash Flow (P/CF)7.40
P/FCF Ratio7.80
Enterprise Value/Market Cap0.76
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.13
Enterprise Value/Ebitda8.71
Forecast
1Y Price Target
$39.14Price Target Upside17.86% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
---
Alkermes News
PremiumCompany Announcements
Regulatory Challenges Pose Significant Risks to Alkermes’ Financial Stability
PremiumCompany Announcements
Alkermes plc Reports Record Revenues in 2024 Earnings Call
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceAlkermes ended 2024 debt-free with a significant cash reserve of $824.8M, which strengthens its financial position.
Revenue GrowthAlkermes reported revenues of $430M in 4Q, well ahead of expectations of $373M, reflecting underlying strength.
Treatment AdvancementsThe KOL was excited about the orexin class, and he believes that it’s poised to transform the treatment paradigm of narcolepsy, especially narcolepsy type1, given the compelling evidence of efficacy and favorable safety demonstrated to-date.
Bears Say
Investor ConcernsInvestors might view the latest financial results as low quality due to the influence of channel inventory fluctuations.
Market ChallengesThe 2025 revenue and EBITDA guidance is below consensus expectations, indicating potential challenges in meeting market predictions.
Sales DeclineThe inventory levels have normalized, leading to an expected substantial sequential sales decline in 1Q25.
---
Ownership Overview
1.48% Insiders
34.35% Mutual Funds
23.35% Other Institutional Investors
8.29% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ALKS FAQ
What was Alkermes’s price range in the past 12 months?
Alkermes lowest stock price was $22.90 and its highest was $36.45 in the past 12 months.
What is Alkermes’s market cap?
Alkermes’s market cap is $5.40B.
When is Alkermes’s upcoming earnings report date?
Alkermes’s upcoming earnings report date is Apr 23, 2025 which is in 24 days.
How were Alkermes’s earnings last quarter?
Alkermes released its earnings results on Feb 12, 2025. The company reported $1.05 earnings per share for the quarter, beating the consensus estimate of $0.759 by $0.291.
Is Alkermes overvalued?
According to Wall Street analysts Alkermes’s price is currently Undervalued.
Does Alkermes pay dividends?
Alkermes pays a Notavailable dividend of $1.639 which represents an annual dividend yield of N/A. See more information on Alkermes dividends here
What is Alkermes’s EPS estimate?
Alkermes’s EPS estimate is 0.31.
How many shares outstanding does Alkermes have?
Alkermes has 162,614,060 shares outstanding.
What happened to Alkermes’s price movement after its last earnings report?
Alkermes reported an EPS of $1.05 in its last earnings report, beating expectations of $0.759. Following the earnings report the stock price went up 4.819%.
Which hedge fund is a major shareholder of Alkermes?
Currently, no hedge funds are holding shares in ALKS
---
Alkermes Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$39.14 (17.86% Upside)
$39.14 (17.86% Upside)
Blogger Sentiment
Bullish
ALKS Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 152.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.3%
Last 30 Days ▲ 11.0%
Last 30 Days ▲ 11.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
22.68%
12-Months-Change
Fundamentals
Return on Equity
27.90%
Trailing 12-Months
Asset Growth
-3.78%
Trailing 12-Months
Company Description
Alkermes
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
---
ALKS Company Deck
---
ALKS Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong financial performance in 2024 with record revenues, significant progress in pipeline development, and strategic debt management. However, challenges such as anticipated reductions in manufacturing and royalty revenues and the need for continued growth in mature product lines present headwinds. The company's strategic focus on profitability and pipeline advancement, particularly with ALKS 2680, positions it well for future growth.Read More>---
ALKS Revenue Breakdown
89.69% U.S.
10.24% Rest of world
0.07% Ireland
---
ALKS Stock 12 Month Forecast
Average Price Target
$39.14
▲(17.86% Upside)
Technical Analysis
Best Analysts Covering ALKS
1 Year
1 Year Success Rate
17/22 ratings generated profit
1 Year Average Return
+12.58%
reiterated a buy rating 2 months ago
Copying Uy Ear's trades and holding each position for 1 Year would result in 77.27% of your transactions generating a profit, with an average return of +12.58% per trade.
---